If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Oncology - General
Sub-Investigator(s):
Sponsors: Internal
Details (Indentifier #): NCT05694338
Title: A Phase 2, Dose-finding, Randomized,
Double-blind, Placebo-controlled, Multicenter
Study to Evaluate the Safety and Efficacy of
Efavaleukin Alfa Induction Therapy in Subjects
with Moderately to Severely Active Ulcerative
Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Matthew Lincoln, DO
Sub-Investigator(s):
Sponsors: Amgen
Details (Indentifier #): NCT04987307
Title: A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine in Healthy Participants ≥5 Years of Age
Department: Internal Medicine
Diagnosis: Infectious Disease
Principal Investigator: Victor Kolade, MD, MS, FACP
Sub-Investigator(s):
Sponsors: Pfizer
Details (Indentifier #): NCT05477524
Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)
Department: Pulmonary
Diagnosis: Lung - COPD
Principal Investigator: Boyd Taylor Hehn, MD
Sponsors: Astra Zeneca
Details (Indentifier #): NCT05166889
Title: A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT04457596
Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Department: Oncology
Diagnosis: Genito-urinary - Renal
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT03793166
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT02194738
Title: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles as Early Goal Directed Therapy for COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS):
Department: Pulmonary
Diagnosis: Infectious Disease
Principal Investigator: James J Walsh, MD, MSHA, FACP, FCCP
Sponsors: Direct Biologics
Details (Indentifier #): NCT05354141
Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Astra Zeneca
Details (Indentifier #): NCT05774951
Title: Cultivate-APD334-202: A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Michael J Georgetson, MD, FACG, FASGE
Sub-Investigator(s):
Sponsors: Arena
Details (Indentifier #): NCT04173273
Showing 1-10 of 30 Results